Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials

By afschroeder • June 8, 2025

Cabanski CR, Yang E, Stewart MD, Allen JD, Connolly JE, Dugan U, Greenberg PD, Mackall CL, June CH, Marson A, Maus MV, Ribas A. Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. J Immunother Cancer. 2025 Jun 5;13(6):e011301. doi: 10.1136/jitc-2024-011301. PMID: 40480658; PMCID: PMC12142127.

Tags: Adoptive cell therapy - ACT, Chimeric antigen receptor - CAR, Gene therapy, Hematology/Oncology, Publications, Solid tumor, T cell Receptor - TCR

Related Posts

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report

Riely GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, Esper R, Felip E, Gelsomino F, Goldman JW, Hussein M, Johnson M, Marrone KA, Morgensztern D, Nadal[...]

A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)

Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC; University[...]

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, Yan M, Tong Z, Liu Y, Wainberg ZA, Wang Y, Geng C, Ulahannan[...]